Cargando…
Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review
Longstanding hyperlipidemia can increase the risk of cardiovascular disease. Statins are currently the mainstay of treatment in hyperlipidemia. Combination therapy of statin with ezetimibe is only indicated for severe hypercholesterolemia and very high-risk atherosclerotic cardiovascular disease (AS...
Autores principales: | Chauhan, Dhruva, Memon, Farzana, Patwardhan, Vaibhav, Kotwani, Priya, Shah, Parth, Samala Venkata, Vikramaditya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717522/ https://www.ncbi.nlm.nih.gov/pubmed/36475227 http://dx.doi.org/10.7759/cureus.31007 |
Ejemplares similares
-
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
por: Rotella, Carlo M, et al.
Publicado: (2010) -
Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia
por: Visseren, F. L. J.
Publicado: (2011) -
Complementary Therapy to Target LDL Cholesterol: The Role of the Ezetimibe/Simvastatin Combination
por: Neal, Ryan C, et al.
Publicado: (2006) -
Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations
por: Górniak, Agata, et al.
Publicado: (2022) -
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011)